Piper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing.
Piper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions. The company offers tests across multiple categories, including hereditary cancer, pharmacogenomics, and women’s health. It pioneered and was the market leader in BRCA testing for over ten y
How do you define a stock market opportunity? Is it a windfall, a piece of luck, or the result of careful planning, a strategy to make the most of any opening? The savvy investor seeks out the latter, looking for stocks that offer inducements to entry, be it a high upside or a depressed share price or a recent positive analyst review – or better yet, a combination of all three. So there’s a profile. We’ve used the TipRanks database to look up two stocks that fit it – stocks with Strong Buy conse
Quest Diagnostics Incorporated (NYSE:DGX) Q3 2023 Earnings Call Transcript October 24, 2023 Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is $2.22, expectations were $2.19. Operator: Welcome to the Quest Diagnostics Third Quarter 2023 Conference Call. At the request of the company, this call is being recorded. The entire contents of the call, including the […]